REG - N4 Pharma PLC - Nanogenics Update

N4 PharmaAnnouncement

03/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240703:nRSC8858Ua&default-theme=true

RNS Number : 8858U  N4 Pharma PLC  03 July 2024

3 July 2024

N4 Pharma plc

("N4 Pharma" or the "Company")

 

Nanogenics Update

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments, gene therapy and
vaccines, is pleased to provide an update on its subsidiary, Nanogenics
Limited ("Nanogenics").

 

Nanogenics has now submitted an application to the U.S. Food and Drug
Administration ("FDA") to obtain orphan drug designation for its product
ECP105, for the prevention of scarring following glaucoma surgery. Obtaining
orphan drug status in the USA is expected to bring substantial cost and time
savings on the development work and once approved, seven years of exclusivity.
A decision is expected by the FDA three months from the date of application.

 

Alongside this, Nanogenics has also filed a patent application in the UK for
novel siRNA sequences that can be used as part of the ECP105 development work.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"Having orphan drug status for ECP105 in the USA will be akin to getting a
patent granted as it provides exclusivity for the treatment indication applied
for.

 

"Alongside applying for orphan drug status in the USA, Nanogenics is
strengthening its IP position by filing a patent for novel siRNA sequences
which can be used to widen its product protection further."

 

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                                  Via N4 Pharma Investor Hub

 Luke Cairns, Executive Director

 Engage with us directly at N4 Pharma Investor Hub                    Sign up at investors.n4pharma.com (https://investors.n4pharma.com/)

 To hear more, visit                                                  https://investors.n4pharma.com/link/WPGM9e
                                                                      (https://investors.n4pharma.com/link/WPGM9e)

 SP Angel Corporate Finance LLP                                       Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                                Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec® and Liptide, a unique
peptide/lipid delivery system via its subsidiary Nanogenics.

 

N4 Pharma's business model is to partner with companies developing products in
these fields to use Nuvec® or Liptide® as the delivery vehicle for these
products. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at investors.n4pharma.com
(https://investors.n4pharma.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUURARSOUBRUR